Seagen Inc.: Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
Results from EV-103 trial evaluating PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) in urothelial cancer to be featured as late-breaking oral session - Seagen Inc. (Nasdaq:SGEN) today